BioCentury
ARTICLE | Company News

AC Immune gets another tau deal in AD

January 13, 2015 3:24 AM UTC

AC Immune S.A. (Lausanne, Switzerland) granted the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) an exclusive worldwide license to develop and commercialize anti-tau vaccine candidate ACI-35 to treat Alzheimer's disease. The two companies also began a three-year research collaboration to develop additional anti-tau vaccines.

AC Immune is eligible for up to $509 million (CHF517.3 million), including an undisclosed upfront payment and development and commercialization milestones. The biotech also is eligible for tiered royalties on products arising from the collaboration. ...